A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment

Trial Profile

A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs OPB 111001 (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Oct 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 28 Apr 2015 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top